REV3L modulates cisplatin sensitivity of non-small cell lung cancer H1299 cells

Wang,Wenjie; Sheng,Wenjiong; Yu,Chenxiao; Cao,Jianping; Zhou,Jundong; Wu,Jinchang; Zhang,Huojun; Zhang,Shuyu

doi:10.3892/or.2015.4121

REV3L modulates cisplatin sensitivity of non-small cell lung cancer H1299 cells

Authors:
- Wenjie Wang
- Wenjiong Sheng
- Chenxiao Yu
- Jianping Cao
- Jundong Zhou
- Jinchang Wu
- Huojun Zhang
- Shuyu Zhang
View Affiliations

Affiliations: School of Radiation Medicine and Protection, and Jiangsu Provincial Key Laboratory of Radiation Medicine and Protection, Medical College of Soochow University, Suzhou 215123, P.R. China, Department of Radio-Oncology, Nanjing Medical University Affiliated Suzhou Hospital, Suzhou 215001, P.R. China, Department of Radiation Oncology, Shanghai Changhai Hospital, the Second Military Medical University, Shanghai 200433, P.R. China
Published online on: July 9, 2015 https://doi.org/10.3892/or.2015.4121
Pages: 1460-1468

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer remains the leading cause of cancer-related mortality worldwide and non-small cell lung cancer (NSCLC) accounts for approximately 80-85% of all cases of lung cancer. Cisplatin plays a significant role in the management of human lung cancer. Translesion DNA synthesis (TLS) is involved in DNA damage repair. DNA polymerase ζ (Pol ζ) is able to mediate the DNA replication bypass of DNA damage, which is suggested to be involved in chemoresistance. REV3L is the catalytic subunit of Pol ζ. Due to its critical role in translesion DNA synthesis, whether REV3L modulates cisplatin response in NSCLC cells remains unknown. In this study, REV3L overexpression and silencing H1299 cell lines were established. The reports showed that cisplatin induced the expression of REV3L by recruiting Sp1 to its promoter. Similar results were obtained when the ability of the cells to express luciferase from a platinated plasmid was measured. Co-transfection of the reporter with the REV3L overexpression vector or REV3L plus REV7L significantly enhanced the reporter activity. Nuclear condensation and fragmentation of shRNA-REV3L H1299 cells were more pronounced than shRNA-NC H1299 cells after cisplatin exposure, indicating that REV3L overexpression abolished cisplatin-induced DNA damage. Moreover, a forced expression of REV3L conferred the resistance of H1299 cells to cisplatin, whereas the knockdown of REV3L sensitized cisplatin efficacy in H1299 cells. Taken together, we demonstrated that inhibition of REV3L sensitized lung cancer H1299 cells to cisplatin treatment. Thus, REV3L may be a novel target for the chemotherapy of NSCLC.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
2	Langer CJ, Mok T and Postmus PE: Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). Cancer Treat Rev. 39:252–260. 2013. View Article : Google Scholar
3	de Boer RH, Arrieta Ó, Yang CH, Gottfried M, Chan V, Raats J, de Marinis F, Abratt RP, Wolf J, Blackhall FH, et al: Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: A randomized, double-blind phase III trial. J Clin Oncol. 29:1067–1074. 2011. View Article : Google Scholar : PubMed/NCBI
4	O'Rourke N, Roqué I, Figuls M, Farré Bernadó N and Macbeth F: Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 6:CD0021402010.PubMed/NCBI
5	Barr MP, Gray SG, Hoffmann AC, Hilger RA, Thomale J, O'Flaherty JD, Fennell DA, Richard D, O'Leary JJ and O'Byrne KJ: Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One. 8:e541932013. View Article : Google Scholar : PubMed/NCBI
6	Einhorn LH: First-line chemotherapy for non-small-cell lung cancer: Is there a superior regimen based on histology? J Clin Oncol. 26:3485–3486. 2008. View Article : Google Scholar : PubMed/NCBI
7	Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, Früh M, Qian W, Tamura T, Samantas E, et al: Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: The COCIS meta-analysis of individual patient data. J Clin Oncol. 30:1692–1698. 2012. View Article : Google Scholar : PubMed/NCBI
8	Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar
9	Wang D and Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 4:307–320. 2005. View Article : Google Scholar : PubMed/NCBI
10	Martin LP, Hamilton TC and Schilder RJ: Platinum resistance: The role of DNA repair pathways. Clin Cancer Res. 14:1291–1295. 2008. View Article : Google Scholar : PubMed/NCBI
11	Basu A and Krishnamurthy S: Cellular responses to Cisplatin-induced DNA damage. J Nucleic Acids. 2010:2013672010. View Article : Google Scholar : PubMed/NCBI
12	Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 7:573–584. 2007. View Article : Google Scholar : PubMed/NCBI
13	Friedberg EC, Lehmann AR and Fuchs RP: Trading places: How do DNA polymerases switch during translesion DNA synthesis? Mol Cell. 18:499–505. 2005. View Article : Google Scholar : PubMed/NCBI
14	Gan GN, Wittschieben JP, Wittschieben BØ and Wood RD: DNA polymerase zeta (pol zeta) in higher eukaryotes. Cell Res. 18:174–183. 2008. View Article : Google Scholar
15	Okada T, Sonoda E, Yoshimura M, Kawano Y, Saya H, Kohzaki M and Takeda S: Multiple roles of vertebrate REV genes in DNA repair and recombination. Mol Cell Biol. 25:6103–6111. 2005. View Article : Google Scholar : PubMed/NCBI
16	Shen X, Jun S, O'Neal LE, Sonoda E, Bemark M, Sale JE and Li L: REV3 and REV1 play major roles in recombination-independent repair of DNA interstrand cross-links mediated by monoubiquitinated proliferating cell nuclear antigen (PCNA). J Biol Chem. 281:13869–13872. 2006. View Article : Google Scholar : PubMed/NCBI
17	Wittschieben JP, Reshmi SC, Gollin SM and Wood RD: Loss of DNA polymerase zeta causes chromosomal instability in mammalian cells. Cancer Res. 66:134–142. 2006. View Article : Google Scholar : PubMed/NCBI
18	Pan Q, Fang Y, Xu Y, Zhang K and Hu X: Down-regulation of DNA polymerases kappa, eta, iota, and zeta in human lung, stomach, and colorectal cancers. Cancer Lett. 217:139–147. 2005. View Article : Google Scholar
19	Zhang S, Chen H, Zhao X, Cao J, Tong J, Lu J, Wu W, Shen H, Wei Q and Lu D: REV3L 3′UTR 460 T>C polymorphism in microRNA target sites contributes to lung cancer susceptibility. Oncogene. 32:242–250. 2013. View Article : Google Scholar
20	Lin X, Trang J, Okuda T and Howell SB: DNA polymerase zeta accounts for the reduced cytotoxicity and enhanced mutagenicity of cisplatin in human colon carcinoma cells that have lost DNA mismatch repair. Clin Cancer Res. 12:563–568. 2006. View Article : Google Scholar : PubMed/NCBI
21	Eastman A, Jennerwein MM and Nagel DL: Characterization of bifunctional adducts produced in DNA by transdiamminedichloroplatinum(II). Chem Biol Interact. 67:71–80. 1988. View Article : Google Scholar
22	Zhang S, Lu J, Zhao X, Wu W, Wang H, Lu J, Wu Q, Chen X, Fan W, Chen H, et al: A variant in the CHEK2 promoter at a methylation site relieves transcriptional repression and confers reduced risk of lung cancer. Carcinogenesis. 31:1251–1258. 2010. View Article : Google Scholar : PubMed/NCBI
23	Jamieson ER and Lippard SJ: Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev. 99:2467–2498. 1999. View Article : Google Scholar
24	Nojima K, Hochegger H, Saberi A, Fukushima T, Kikuchi K, Yoshimura M, Orelli BJ, Bishop DK, Hirano S, Ohzeki M, et al: Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells. Cancer Res. 65:11704–11711. 2005. View Article : Google Scholar : PubMed/NCBI
25	Lange SS, Takata K and Wood RD: DNA polymerases and cancer. Nat Rev Cancer. 11:96–110. 2011. View Article : Google Scholar : PubMed/NCBI
26	Albertella MR, Green CM, Lehmann AR and O'Connor MJ: A role for polymerase eta in the cellular tolerance to cisplatin-induced damage. Cancer Res. 65:9799–9806. 2005. View Article : Google Scholar : PubMed/NCBI
27	Alt A, Lammens K, Chiocchini C, Lammens A, Pieck JC, Kuch D, Hopfner KP and Carell T: Bypass of DNA lesions generated during anticancer treatment with cisplatin by DNA polymerase eta. Science. 318:967–970. 2007. View Article : Google Scholar : PubMed/NCBI
28	Wu F, Lin X, Okuda T and Howell SB: DNA polymerase zeta regulates cisplatin cytotoxicity, mutagenicity, and the rate of development of cisplatin resistance. Cancer Res. 64:8029–8035. 2004. View Article : Google Scholar : PubMed/NCBI
29	Okuda T, Lin X, Trang J and Howell SB: Suppression of hREV1 expression reduces the rate at which human ovarian carcinoma cells acquire resistance to cisplatin. Mol Pharmacol. 67:1852–1860. 2005. View Article : Google Scholar : PubMed/NCBI
30	Lin X, Okuda T, Trang J and Howell SB: Human REV1 modulates the cytotoxicity and mutagenicity of cisplatin in human ovarian carcinoma cells. Mol Pharmacol. 69:1748–1754. 2006. View Article : Google Scholar : PubMed/NCBI
31	Cheung HW, Chun AC, Wang Q, Deng W, Hu L, Guan XY, Nicholls JM, Ling MT, Chuan Wong Y, Tsao SW, et al: Inactivation of human MAD2B in nasopharyngeal carcinoma cells leads to chemosensitization to DNA-damaging agents. Cancer Res. 66:4357–4367. 2006. View Article : Google Scholar : PubMed/NCBI
32	Wang H, Zhang SY, Wang S, Lu J, Wu W, Weng L, Chen D, Zhang Y, Lu Z, Yang J, et al: REV3L confers chemoresistance to cisplatin in human gliomas: The potential of its RNAi for synergistic therapy. Neurooncol. 11:790–802. 2009.
33	Tan NY and Khachigian LM: Sp1 phosphorylation and its regulation of gene transcription. Mol Cell Biol. 29:2483–2488. 2009. View Article : Google Scholar : PubMed/NCBI
34	Fojas de Borja P, Collins NK, Du P, Azizkhan-Clifford J and Mudryj M: Cyclin A-CDK phosphorylates Sp1 and enhances Sp1-mediated transcription. EMBO J. 20:5737–5747. 2001. View Article : Google Scholar : PubMed/NCBI
35	Iwahori S, Yasui Y, Kudoh A, Sato Y, Nakayama S, Murata T, Isomura H and Tsurumi T: Identification of phosphorylation sites on transcription factor Sp1 in response to DNA damage and its accumulation at damaged sites. Cell Signal. 20:1795–1803. 2008. View Article : Google Scholar : PubMed/NCBI
36	Ryu H, Lee J, Zaman K, Kubilis J, Ferrante RJ, Ross BD, Neve R and Ratan RR: Sp1 and Sp3 are oxidative stress-inducible, antideath transcription factors in cortical neurons. J Neurosci. 23:3597–3606. 2003.PubMed/NCBI
37	Meighan-Mantha RL, Riegel AT, Suy S, Harris V, Wang FH, Lozano C, Whiteside TL and Kasid U: Ionizing radiation stimulates octamer factor DNA binding activity in human carcinoma cells. Mol Cell Biochem. 199:209–215. 1999. View Article : Google Scholar : PubMed/NCBI
38	Grande L, Bretones G, Rosa-Garrido M, Garrido-Martin EM, Hernandez T, Fraile S, Botella L, de Alava E, Vidal A, Garcia del Muro X, et al: Transcription factors Sp1 and p73 control the expression of the proapoptotic protein NOXA in the response of testicular embryonal carcinoma cells to cisplatin. J Biol Chem. 287:26495–26505. 2012. View Article : Google Scholar : PubMed/NCBI